MAPT and early-onset autosomal dominant Alzheimer disease: The same research group employed the nanoFPI to detect beta-amyloid (Ab42) and total tau (T-tau) biomarkers in cerebrospinal fluid (CSF) for the diagnosis of Alzheimer’s diseases [45].